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The occurrence of multiple primary cancer within the same organ
has been widely reported. The incidence of multiple lung cancers
in reported clinical series ranges from 1% to 7% (Ferguson et al,
1985), and autopsy studies have revealed more accurately that the
incidence of multiple primary tumours in the lung ranges from
3.5% to 14% (Mathisen et al, 1984). When we identify multiple
synchronous lung tumours, differentiating multicentric lung
cancers, a single lung cancer with intrapulmonary metastases, or
pulmonary metastases from primary cancer in different organs can
often be difficult, especially when multiple tumours are found in
the same lobe. There are no specific clinical or radiologic features
that can differentiate the multiple primary lung cancers and intra-
pulmonary metastases. Non-small cell lung cancer cases with
intrapulmonary metastasis were divisible into two subgroups of
patients, one with a good post-surgical prognosis and one with a
poor outcome, and there is a possibility that pulmonary metastases
with good prognosis may be multicentric lung cancers (Naruke et
al, 1988; Nakajima et al, 1996). Several reports have suggested
that the incidence of synchronous double primary lung cancer
might be higher than predicted and they have advocated an aggres-
sive treatment plan for double primary lung cancer cases
(Ferguson et al, 1985; Mathisen et al, 1984; Kunitoh et al, 1992;
Martini et al, 1975).
p53 mutation is one common genetic change in non-small cell
lung cancers (Chiba et al, 1990; Caamano et al, 1991; Mitsudomi
et al, 1992; Kishimoto et al, 1992). It has been demonstrated that
the p53 mutation usually precedes metastasis and is conserved in
metastases (Chung et al, 1993; Li et al, 1994; Zheng et al, 1994).
On the other hand, the p53 mutation pattern has been used to
distinguish primary tumour from metastasis and/or second primary
tumour from recurrence in various organ tumours, such as hepato-
cellular carcinomas (Oda et al, 1992), ovarian cancers (Mock et al,
1992), urothelial carcinomas (Habuchi et al, 1993), and head and
neck cancers (Gasparotto et al, 1995; Nees et al, 1993). With
respect to the lung cancer, comparison of p53 mutations between
primary lung cancer and metastatic lung tumour (Kandioler et al,
1996), primary lung tumour and metastases to other organs
(Schlegel et al, 1992; Reichel et al, 1994), or second primary lung
cancer and metastasis (Sozzi et al, 1995; Mitsudomi et al, 1997)
has been reported. However, discrimination of multicentric lung
cancers from pulmonary metastasis has never been examined in
synchronous double lung tumour cases.
It is possible that synchronous double primary lung cancer has
been misdiagnosed as single lung cancer with pulmonary metas-
tasis in some cases. In this study, we examined 20 patients with
synchronous double lung tumours diagnosed as primary lung
cancer with intrapulmonary metastasis by clinical and histological
findings to clarify the clonal origin of these tumours using p53
gene mutation as a clonal marker.
MATERIALS AND METHODS
Patients and DNA extraction
Histological reports of patients who underwent lung resection for
primary lung cancer at the Second Department of Surgery of
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reviewed. Twenty of 861 patients were selected in accordance with
the following criteria: they had synchronous double solid tumours
(1) in the unilateral lung, (2) without distant metastases, (3) of the
same histological type, and (4) diagnosed as intrapulmonary
metastasis by clinical and histological findings. Paired tumours
from these 20 patients were analysed. Sections of tumours 30-mm
thick were prepared from each formalin-fixed, paraffin-embedded
block after as much of the normal tissues around the tumour as
possible were cut away. The sections were deparaffinized with
three successive xylene extractions, rinsed once each with 100%,
90% and 70% ethanol, and air dried. Samples were incubated in
500mMTris-HCl (pH 8.0), 20mMethylenediamine tetra-acetic
acid (EDTA), containing 1% sodium dodecyl sulphate and 1mg
ml–1 proteinase K for 96h at 42°C. DNAs were purified by
extracting twice with one volume of phenol–chloroform–isoamyl-
alcohol (25:24:1) and twice with one volume of chloroform–
isoamylalcohol (24:1), precipitating with ethanol, rinsing twice
with 70% ethanol and dissolved in 10mMTris-HCl, 1mMEDTA
(pH 8.0).
Polymerase chain reaction, single-strand conformation
polymorphism analysis and sequence analysis
Because most (95–98%) of the mutations in the p53 gene in
human cancers have been found in exons 5–9, these exons were
separately amplified by polymerase chain reaction (PCR) and
subjected to single-strand conformation polymorphism (SSCP)
analysis. The sequences of primers used to amplify exons 5–9 are
given in Table 1. Because of the limited length of DNA extracted
from formalin-fixed speciments, PCR products were sized less
than 200 base pairs. Exons 5 and 8 were each divided into two
overlapping fragments. Samples were electrophoresed in 10 or
12% non-denaturing polyacrylamide gels with and without 10%
glycerol at room temperature. The DNA fragments were detected
by silver staining with the Silver Stain ‘DAIICHI’ (Daiichi Pure
Chemicals, Tokyo, Japan). PCR products showing abnormal SSCP
band patterns were purified from a 2% agarose gel and cloned into
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Table 1Oligonucleotide sequences used for p53 gene amplification and
length of amplified fragments
Length
Exon Amplification (bp)
5-f s 5¢-TGTCTCCTTCCTCTTCCT-3¢ 137
a 5¢-TGTAGATGGCCATGGCG-3¢
5-l s 5¢-CTGTGGGTTGATTCCACA-3¢ 144
a 5¢-CAGCCCCAGCTGCTCA-3¢
6s 5¢-TGATTCCTCACTGATTGCTC-3¢ 160
a 5¢-GAGACCCCAGTTGCAAACC-3¢
7s 5¢-TCTTGGGCCTGTGTTATCTC-3¢ 171
a 5¢-AGCAGGCCAGTGTGCAGG-3¢
8-f s 5¢-CTTACTGCCTCTTGCTTCTC-3¢ 122
a 5¢-AGATTCTCTTCCTCTGTGCG-3¢
8-l s 5¢-TTTGAGGTGCGTGTTTGTGC-3¢ 135
a 5¢-CGCTTCTTGTCCTGCTTGC-3¢
9s 5¢-CTTTTATCACCTTTCCTTGCC-3¢ 137
a 5¢-TCCACTTGATAAGAGGTCCC-3¢
f, first half; l, latter half; s, sense primer; a, antisense primer.
ABN
Case 9
ABN
Case 15
ABN
Case 16
Figure 1Cases representative of three different distribution patterns of p53
mutations in double lung tumours. DNAs from different tumours of the same
patient (A and B) and a normal control (N) were analysed. Case 9 showed
different mutations in the tumours. Case 15 showed the mutation in only one
tumour. Case 16 showed the same mutation in both tumours
Table 2Mutations of the p53 gene in double lung tumours
p53 mutations
Age Size
Case (yr) Sex Tumour Site (cm) Histology Tumour Metastatic lymph node
4 77 M 4A LU 7.0 Sq Codon 158 CGC ®TGC No metastasis
4B LU 1.5 Sq Codon 138 GCC ®GTC
9 68 M 9A RU 6.0 Ad Codon 233 CAC ®TAC No metastasis
9B RU 1.5 Ad Codon 260 TCC ®TCT
10 74 M 10A LU 5.0 Sq Codon 237 ATG ®ATT No metastasis
10B LU 1.5 Sq No mutation
15 67 M 15A RM 4.5 Ad Codon 250 CCC ®CTC No metastasis
15B RM 2.0 Ad No mutation
16 64 M 16A RU 4.0 Ad Codon 268 AAC ®AAT Codon 268 AAC ®AAT
16B RU 2.0 Ad Codon 268 AAC ®AAT
19 62 M 19A LU 6.0 Sq No mutation Codon 250 CCC ®CTC
19B LU 1.5 Sq Codon 250 CCC ®CTC
20 49 F 20A LL 4.0 Sq No mutation Codon 143 GTG ®GCG
20B LU 1.5 Sq Codon 143 GTG ®GCG
M, male; F, female; LU, left upper lobe; RU, right upper lobe; RM, right middle lobe; LL, left lower lobe; Sq, squamous cell carcinoma; Ad, adenocarcinoma.a TA cloning vector (Invitrogen, San Diego, USA). Each ligation
reaction was transformed into competent JM 109 cells (Toyobo
Osaka, Japan). The resulting colonies were picked up and then the
colony containing mutated p53 was identified by PCR-SSCP
analysis as described above. The plasmid DNA was isolated from
each identified clone and sequenced by using the T7 Sequenase
v2.0 DNA Sequencing Kit (Amersham, Ohio, USA).
RESULTS
Seven out of 20 (35%) cases showed abnormally shifted bands of
the p53 gene in at least one tumour in the SSCP analysis (Figure
1). No abnormality was found in the remaining 13 cases. Of the
seven cases, both tumours were located in the same lobe in six
cases and in different lobes in one case (Table 2). Histologically,
four cases were squamous cell carcinomas and three cases were
adenocarcinomas. Three cases (cases 4, 19 and 20) underwent
pneumonectomy, and the others underwent lobectomy. Three
patients died within 6 months after the operation (cases 4, 15 and
20). Only two patients survived more than 2 years (cases 10 and 19
for 6 years and 25 months respectively) after the operation.
Mutations in the p53 gene were confirmed by the DNA
sequencing analysis of the PCR product (Figure 2). Four cases
(cases 10, 15, 19 and 20) had p53 mutations in only one tumour.
Two cases (cases 4 and 9) had different mutations specific to each
tumour. One case (case 16) had the same mutation in both tumours.
Three of seven cases had lymph node metastasis, and these nodules
were analysed further. All of the metastatic lymph nodes were found
to have the p53 gene mutations. In cases 19 and 20, the mutation in
metastatic lymph node was identical to that in the tumour with p53
mutation. In case 16, both the pair of tumours and lymph node
metastasis had the same mutation. A possibility of germline muta-
tion in this case was excluded by certifying that no genetic changes
were found in the normal lung tissue. In this study, we did not
evaluate the p53 protein expression using immunohistochemistry.
DISCUSSION
Clinically, human tumours can be divided into three groups:
premalignant lesions, primary tumours and metastases. Normal
cells or premalignant cells become malignant after accumulation
of genetic alterations. The malignant cells have a growth advan-
tage and begin clonal expansion to produce primary tumours.
During expansion of the converted cells at the primary site, new
clones with more malignant phenotypes appear along with addi-
tional genetic alterations in some of the converted cells (Yokota
and Sugimura, 1993). Metastatic nodules are produced by highly
selected and progressed cells that are more invasive and highly
metastatic. They contain the genetic alterations including muta-
tions in the p53 gene that are necessary to maintain the malignant
phenotypes acquired during the progression. p53 mutation usually
precedes metastasis and is conserved in metastases (Chung et al,
1993; Li et al, 1994; Zheng et al, 1994), so analysis of the p53
mutation pattern can be used as a clonal marker for the differential
diagnosis of multiple cancers (Oda et al, 1992).
We identified three different distribution patterns of p53 muta-
tions in the double lung tumours in this study: [A] only one tumour
had the mutation, [B] each tumour had different mutation, and [C]
the same mutation was found in both tumours. The cases of the [A]
or [B] pattern were considered to be multicentric or double primary
lung cancers, because patterns [A] and [B] indicated the hetero-
geneity of p53 mutation in the double tumours and suggested that
each tumour arose from a different cellular clone. The cases of
pattern [C] may be classified as the primary and intrapulmonary
metastatic tumours. Another possibility is that cases of multicentric
lung cancers could show pattern [C] by possessing the same muta-
tion by chance. It is well known that there are mutational hotspots
in the p53 gene (Hollstein et al, 1991; Taylor et al, 1994), the prob-
ability that the same mutation at codon 268 occurred independently
in different tumours is, however, extremely low when the great
variety of p53 mutations is considered.
In cases 19 and 20, the lymph node metastases were suggested
to be derived from the smaller tumour because of the same
mutational pattern of the p53 gene. p53 mutation may be a more
important factor than the size of the tumour in metastasizing.
The mutational patterns and nucleotide substitutions in the p53
gene are specific to each organ. For instance, G:C ®A:T conver-
sion is found in 63% of the p53 mutations in colon cancers, while
its frequency is only 24% in lung cancers. In contrast, G:C®T:A
conversion is found only in 9% of the p53 mutations in colon
cancers and 40% in lung cancers (Greenblatt et al, 1994). This
suggests that different carcinogens and different mechanisms of
p53 alterations occur in each organ. In our study, C®T alterations
accounted for six of eight (75%) independent mutations found in
the multicentric cancers. There might be some particular events in
the carcinogenesis of double primary lung cancer.
It is to be desired that the diagnosis of double primary lung
cancer or pulmonary metastasis should be made before surgery if
possible, because the clinical course and post-operative therapy
may be changed by the diagnosis. Genes can be amplified by PCR
from a very small amount of tissue obtained, for example, by a
bronchial biopsy specimen at the time of bronchoscopy. Use of
p53 alterations as a genetic marker to classify the double lung
tumours may not be complete, because p53 mutations would not
be found in all cases. However, there is a possibility that multi-
centric lung cancers and pulmonary metastasis can be differenti-
ated by using p53 alterations, at least for a subset of lung tumours
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Figure 2 Sequencing analysis of the p53 gene mutations in tumours: (9A)
mutation in codon 233; (9B) mutation in codon 260; (15A) mutation in codon
250; (16A) mutation in codon 268with p53 gene mutations. Although the number of cases analysed
was small, this study suggested that there were more multicentric
cancer cases than the pulmonary metastatic cases in the double
lung tumour cases. Our results support that the incidence of
synchronous double primary lung cancer may be higher than
predicted.
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